Effect on glycemic control by short- and long-term use of continuous glucose monitoring in clinical practice

• Published in: Journal of diabetes science and technology Vol. 5; no. 6; pp. 1472 - 1479
• Main Authors: Anderson, Jenny, Attvall, Stig, Sternemalm, Lennart, Pivodic, Aldina, Fahlén, Martin, Hanås, Ragnar, Ekeroth, Gunnar, Lind, Marcus
• Format: Journal Article
• Language: English
• Published: United States Diabetes Technology Society 01.11.2011
• Subjects: Adult; Blood Glucose - analysis; Clinical Medicine; Diabetes Mellitus - blood; Diabetes Mellitus - drug therapy; Diabetes Mellitus/blood/drug therapy; Female; Glycated Hemoglobin A - analysis; Glycosylated/analysis; Hemoglobin A; Humans; Hypoglycemia - prevention & control; Hypoglycemic Agents - therapeutic use; Insulin - therapeutic use; Klinisk medicin; Male; Monitoring; Monitoring, Physiologic - methods; Original; Physiologic/methods; Sweden
• ISSN: 1932-2968; 1932-3107
• DOI: 10.1177/193229681100500622

In Sweden, patients with diabetes mellitus frequently receive short-term (<3 months) continuous glucose monitoring (CGM) to study glucose patterns or long-term CGM to treat poor glycemic control or severe hypoglycemia. The effects of CGM on glycemic control in clinical practice in relation to indication and duration of use has not been completely studied. Patients with diabetes, among which 99% were diagnosed as type 1, receiving CGM at 10 outpatient clinics in Sweden were studied retrospectively. Long-term use of CGM was defined as ≥ 3 months use of CGM and short-term as <3 months. A control group matched on start date and date of latest value 3 months after the start was selected for both long- and short-term groups. In 34 long-term users of CGM, over a mean follow-up of 1.1 years, the adjusted mean difference of hemoglobin A1c (HbA1c) compared with controls (n = 408) was -0.76 (95% confidence interval -1.17; -0.33, p < .001). Long-term users with indications for high HbA1c (n = 15) had a reduction of 1.2% in HbA1c from 10.1 to 8.9% (p = .003), whereas patients with hypoglycemia as their indication (n = 16) decreased by 0.3% (p = .17). Nonsevere hypoglycemic events decreased in long-term users within the same follow-up period (p = .004). Short-term users showed no statistically significant improvement in HbA1c compared with controls at 1.1 years (n = 41), p = .85 or at 2.6 years (n = 43), p = .19. Long-term CGM use was associated with improved glycemic control in clinical practice and a reduction in nonsevere hypoglycemic events, whereas short-term use had no effect on HbA1c. The effect on glycemic control varied by indication.